Compare SWX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWX | PCVX |
|---|---|---|
| Founded | 1931 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | SWX | PCVX |
|---|---|---|
| Price | $83.99 | $54.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $87.40 | ★ $105.00 |
| AVG Volume (30 Days) | 419.8K | ★ 1.1M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | ★ 157.10 | N/A |
| EPS | ★ 6.42 | N/A |
| Revenue | ★ $4,649,933,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.00 | ★ N/A |
| Revenue Growth | ★ 41.35 | N/A |
| 52 Week Low | $64.69 | $27.66 |
| 52 Week High | $86.75 | $93.77 |
| Indicator | SWX | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.13 | 71.40 |
| Support Level | $82.70 | $50.70 |
| Resistance Level | $84.29 | $56.04 |
| Average True Range (ATR) | 1.58 | 2.68 |
| MACD | 0.03 | 0.87 |
| Stochastic Oscillator | 49.62 | 90.60 |
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution and Utility Infrastructure Services units. The first of these encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. The natural gas distribution division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers. The Utility Infrastructure Services segment generates the other half of the company's total revenue from the underground piping contractor services that its subsidiary, Centuri Construction Group, provides.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.